MedTrace Logo

A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults

NCT06137729 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-11-25

No results posted yet for this study

Summary

The purposes of the study are as follows:

* To understand how safe and tolerable are different amounts of study medicine (PF-07899895).
* To measure the amount of PF-07899895 in blood after the medicine is taken by mouth.

The study is seeking participants who:

* Are male or female of 18 to 65 years of age.
* Are in good health condition.
* Have not had viral infections (HIV, HBV, or HCV). HIV, human immunodeficiency virus. - HBV, human hepatitis B virus. HCV, human hepatitis C virus.
* Have tested negative for tuberculosis.

Participants will receive either PF-07899895 or placebo (dummy pill) by chance. In the first part of the study (Part A):

* each participant will receive a total of up to 5 doses of the medicine or placebo with at least 5 days between each dose.
* after each dose, participants will stay in study clinic for 3 to5 days.

In the second part of the study (Part B):

\- each participant will need to take 10 days of dosing and will stay in the study clinic for clinical checks for 13 days.

In the third part of the study (Part C):

* In SD cohort, each participant will receive a total of up to 5 doses of the medicine or placebo with at least 7 days between each dose. After each dose, participants will stay in study clinic for 5 days.
* In MD cohorts, each participant will need to take 10 days of dosing and will stay in the study clinic for clinical checks for 13 days.

The planned duration of participation from screening to follow-up in:

* Part A of the study is up to 15 to 18 weeks.
* Part B of the study is up to 11 weeks.
* Part C of the study is up to 15 to 18 weeks. Participants will also have their blood collected by the study doctors for several times.

Conditions

  • Healthy

Interventions

DRUG

PF-07899895

Participants will receive oral ascending doses.

DRUG

Placebo

Participants will receive matching placebo.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-17
Primary Completion
2025-10-24
Completion
2025-10-24
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137729 on ClinicalTrials.gov